SEC Form 4 · accession 0001104659-15-004878
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Sanofi
10% Owner
Period of report
Jan 22, 2015
Accepted (ET)
Jan 28, 2015 · 6:51 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 22, 2015 | P | 196,251 | $9,317.00 | A | 9,307,037 | I | Via wholly-owned subsidiary, Genzyme Corp. |
| Common StockF1 | Jan 26, 2015 | P | 647,448 | $95.00 | A | 9,954,485 | I | Via wholly-owned subsidiary, Genzyme Corp. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Genzyme Corporation entered into a 60-day lock-up agreement (which may be extended under certain circumstances) which covers the 843,699 newly acquired shares.